Adverum Biotechnologies
ADVM
About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Employees: 155
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
11.49% less ownership
Funds ownership: 78.54% [Q1] → 67.06% (-11.49%) [Q2]
17% less funds holding
Funds holding: 70 [Q1] → 58 (-12) [Q2]
25% less call options, than puts
Call options by funds: $3K | Put options by funds: $4K
38% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 29
57% less capital invested
Capital invested by funds: $69.8M [Q1] → $30.1M (-$39.7M) [Q2]
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Chardan Capital
Daniil Gataulin
|
$33
|
Buy
Maintained
|
13 Aug 2025 |
|
Mizuho
Graig Suvannavejh
|
$12
|
Outperform
Maintained
|
26 Jun 2025 |
Financial journalist opinion
